Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Abbott Laboratories
abbott.comAI Executive Summary
AI-powered analysis of 8-K filing content
Abbott Laboratories reported its Q1 2026 financial results on April 16, 2026, including non-GAAP adjusted earnings that exclude acquisition-related and stock-based compensation expenses. This routine earnings announcement provides investors with adjusted financial metrics to assess operational performance.
Key Takeaways
Abbott reported Q1 2026 financial results with non-GAAP adjustments for acquisition and restructuring expenses
The company uses non-GAAP measures to present adjusted earnings excluding specified items related to acquisitions and stock-based compensation
2 more takeaways
Related Filings (2)
2 more filings from Abbott Laboratories in the last 90 days